Merck KGaA sharpens budget ax for new round of cuts; Isis gains $25M milestone on Sanofi's mipomersen NDA;

@FierceBiotech: 23andMe stakes a claim on Parkinson's gene. More | Follow @FierceBiotech

@JohnCFierce: Phase III starts in June: Sanofi/Regeneron add to stockpile of promising PCSK9 LDL drug data. Item | Follow @JohnCFierce

> Merck KGaA is reportedly preparing a fresh round of job cuts in Europe. Dow Jones reports that the pharma company may virtually shutter a facility in Lyon, France, cutting 450 workers. Story

> Isis has scored a $25 million milestone payment following the FDA's acceptance of Sanofi's application for mipomersen (Kynamro),a new drug for omozygous familial hypercholesterolemia developed by Genzyme. Release

> Cambridge, MA-based Ensemble Therapeutics has inked a drug discovery collaboration with Genentech. Release

> Tranzyme Pharma has received solid supporting data demonstrating that its gastrointestinal drug ulimorelin doesn't work as hoped. A second Phase III study shows it didn't work any better than a placebo. Story

> Bungled analysis forces Vertex to revise cystic fibrosis drug data. News

> Lilly backs $150M Montreal biotech fund for single-project startups. Story

> Insider accounts spur a reported bidding war for Amylin. Article

> Senator takes a stab at repeating biotech R&D credit program. More

Pharma News

@FiercePharma: Remember that U.K. recall where Seroquel packs got into boxes of a popular painkiller? The perp is in jail for 18 months. Story | Follow @FiercePharma

> Big Pharma sweats outcome of Supreme Court ruling. Report

> Teva says no thank you to generic Lipitor. News

> Roche tightens credit for long-past-due hospitals in Spain, Portugal. Item

> Sanofi, Merck reportedly place bids for Amylin. Article

Medical Devices News

@FierceMedDev: Arizona State researchers are working with NASA to develop a way to diagnose bone loss by testing calcium in urine. Story | Follow @FierceMedDev

@MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Boston Scientific's GI balloon dilator gains expanded FDA nod. Report

> Investors pursue medical devices that can do a drug's job. News

> FDA wants reanalysis of St. Jude heart implant. Item

> Siemens victory stands in ruling over PET scanner imaging crystal patents. Article

Pharma Manufacturing News

> Drug shortages deepen as Pakistan debates price controls. Story

> Ranbaxy hires U.S. consultants under consent decree. Report

> Hospira overfills far greater than first thought. More

> As manufacturing capacity halves, CMO revenue could double in Europe. Analysis

Biotech IT News

> BGI and Big Pharma probe trigger of liver cancer. Article

> 23andMe stakes a claim on Parkinson's gene. Item

> Roche re-enlists software for personalized medicine research. News

> Broken link found in electronic clinical trial startups. Report

Biotech Research News

> Scientists decipher how T cells hunt down infection. Story

> Embryonic stem cells treat neuropathic pain in preclinical success. More

> New peptide compound triggers enhanced tumor cell death. News

> Dangerous antipsychotic shows leukemia-fighting promise in mice. Article

And Finally…The discovery of a mummified Korean child with fairly well preserved organs allowed a scientific team to reveal a unique hepatitis B virus genotype C2 sequence which is common in Southeast Asia. Release

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.